Generation of circulating tumor cell derived organoids through enrichment by leukapheresis - A novel drug screening system in metastatic prostate cancer

Generation of circulating tumor cell derived organoids through enrichment by leukapheresis - A novel drug screening system in metastatic prostate cancer - Circle study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON46104

Enrollment

Registered

2016-09-16

Start date

2016-12-02

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer prostate carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - metastasized prostate cancer - age * 18 years - Written informed consent of the patient - * 2 adequate peripheral veins as access point for leukapheresis

Exclusion criteria

Exclusion criteria: - CTC count of

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the success rate of culturing organoids from CTCs obtained by LA.	—

Secondary

Measure	Time frame
Secondary endpoints include the fraction of metastatic PCa patients who have * 300 viable CTCs obtained by LA and the exploratory analysis comparing drug sensitivity in organoids to therapy response of the matching patient in the clinic.	—

Countries

Netherlands

Outcome results